title: Vismodegib: a review.
abstract: In January 2012, vismodegib (Erivedge, manufactured by Genentech) became the first selective inhibitor of the Hedgehog signaling pathway to be approved by the US Food and Drug Administration for the treatment of locally advanced and metastatic basal cell carcinoma. The drug selectively binds to Smoothened, a 7-helix transmembrane receptor, thereby inhibiting activation of transcription factors of the glioma-associated oncogene family and suppressing tumor proliferation and growth. Studies published to date have assessed the efficacy of vismodegib according to clinical and radiologic outcomes but little information is available on the molecular mechanisms underpinning the proven clinical efficacy of the drug. This review will cover recent data on the Hedgehog signaling pathway and data from clinical trials with vismodegib in the treatment of basal cell carcinoma, and will consider its use in other types of tumor.
authors.affiliation: Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España. Electronic address: v.ruizsalas@hotmail.com.
authors.forename: V
authors.initials: V
authors.lastname: Ruiz-Salas
authors.affiliation: Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: M
authors.initials: M
authors.lastname: Alegre
authors.affiliation: Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: A
authors.initials: A
authors.lastname: López-Ferrer
authors.affiliation: Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España.
authors.forename: J R
authors.initials: JR
authors.lastname: Garcés
mesh_terms: D000813:Anilides / Q000494:pharmacology / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D053823:Hedgehog Proteins / Q000187:drug effects / Q000502:physiology; D006801:Humans; D011725:Pyridines / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000813:Anilides; D053823:Hedgehog Proteins; C538724:HhAntag691; D011725:Pyridines
keywords: Basal cell carcinoma; Carcinoma basocelular; Hedgehog pathway; Vismodegib; Vía Hedgehog